{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.4","upperLimit":"99.4","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Percentage of patients experiencing grade 3 or higher adverse events will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. All patients who receive at least one dose of protocol therapy will be considered in the evaluation of toxicity.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive vemurafenib PO BID on day 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Vemurafenib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From enrollment to 30 days after the end of treatment, up to 2 years","title":"Percentage of Patients Experiencing Grade 3 or Higher Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of participants"}